Rush testing if genetic clues identify best candidates for Parkinson's surgery

September 1, 2017
Rush Neurologist Gian Pal, MD, MS, the primary investigator for the National Institute of Health-funded clinical study Parkinson disease and DBS: cognitive effects in GBA mutation carriers. Credit: Rush Photo Group

In the first ever clinical investigation involving genetic screening for Parkinson's disease, researchers are testing whether the presence of a specific genetic mutation identifies which patients are the best candidates for deep brain stimulation surgery, and whether neurologists should perform that procedure differently based on that genetic information.

"We are at a very promising time in Parkinson's (PD) research. Finding the connections between the vast amounts of genetic data and cognitive data we are gathering will allow us to tailor future therapies based on genetic biomarkers," said Rush neurologist Gian Pal, MD, MS, the primary investigator for the National Institute of Health-funded clinical study "Parkinson disease and DBS: cognitive effects in GBA mutation carriers"

Deep brain stimulation (DBS) is a surgical procedure in which a battery-operated medical device implanted in the brain delivers electrical stimulation to specific areas in the brain that control movement, thus altering the abnormal signals that cause many PD motor symptoms.

DBS is typically used for individuals whose symptoms cannot be adequately controlled with medication and has proven to dramatically improve and potentially reduce medication burden for many PD patients.

Research suggests that patients who carry a mutation in the glucocerebrosidase (GBA) gene may respond differently to DBS than those who do not carry the mutation. These GBA mutation carriers compose 10-17 percent of subjects undergoing DBS, and typically have higher deposits of alpha-synuclein protein in the brain. Abnormal accumulation of alpha-synuclein is thought to be a key reason for the development and progress ion of PD. These higher levels of alpha-synuclein in patients with the GBA mutation carriers may translate to even more problems with thinking, movement, behavior, and mood than expected in typical PD. Dr. Pal and colleagues are hoping to understand how DBS affects motor function and cognition in these GBA mutation carriers over time.

"If we can determine how GBA mutation carriers respond to DBS, we can better counsel patients on expectations from the surgery, and potentially target a different region of the brain to maximize the benefit and minimize side effects from the surgery. This would be the first time that genetics would inform a clinical decision in the field of PD"

"Deep stimulation is a tremendous option for many Parkinson's disease patients, but not all," said Pal, who is developing a programmatic line of research involving genetics and surgical treatments for PD at the Rush Parkinson's Disease and Movement Disorders Program.

The Rush Parkinson's Disease and Movement Disorders Program is one of the largest and oldest such centers in the country, treating more than 2,000 annually. Rush has been a longstanding Parkinson's Disease Foundation Center of Excellence, based on decades of clinical and research excellence, and is now also recognized as a National Parkinson Foundation Center of Excellence as well.

Explore further: Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

Related Stories

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

Stemming the flow: Stem cell study reveals how Parkinson's spreads

February 18, 2016
Stem cell research published today offers up new clues as to how Parkinson's spreads from cell to cell, a process which has evaded researchers for decades.

Early intervention may be possible for Parkinson's disease

December 9, 2016
One of the largest post-mortem brain studies in the world has confirmed that a protein (LRRK2) associated with the development of Parkinson's disease is increased in the pre-symptom stages, leading researchers to believe ...

Re­search­ers cor­rect Par­kin­son's mo­tor symp­toms in mice

December 15, 2016
A research group led by University of Helsinki Docent Timo Myöhänen has succeeded in correcting the motor symptoms associated with Parkinson's disease in mice. These results are promising in terms of treatment, since Parkinson's ...

Failure in recycling cellular membrane may be a trigger of Parkinson's

February 23, 2017
A genetic mutation found in patients with early-onset Parkinson's disease has been used to create a mouse model of the disease. The advance adds to growing evidence that—at least in a subset of patients—the neurodegenerative ...

Team finds that drug used for another disease slows progression of Parkinson's

October 8, 2014
A new study from UCLA found that a drug being evaluated to treat an entirely different disorder helped slow the progression of Parkinson's disease in mice.

Recommended for you

Researchers find new path to promising Parkinson's treatment

September 19, 2017
Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

Medical history can point to earlier Parkinson's disease diagnosis

September 15, 2017
Before symptoms become pronounced, there is no reliable way to identify who is on track to develop Parkinson's disease, a debilitating movement disorder characterized by tremors, slowness of movement, stiffness, and difficulty ...

Brain rewiring in Parkinson's disease may contribute to abnormal movement

September 14, 2017
The brain's own mechanisms for dealing with the loss of dopamine neurons in Parkinson's disease may be a source of the disorder's abnormal movement, according to a Northwestern Medicine study published in Neuron.

Treating with antioxidants early in Parkinson's disease process may halt degeneration and improve neuronal function

September 7, 2017
Northwestern Medicine scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson's disease (PD) and figured out how to interrupt it, reports a study to be published September ...

New diagnostic tool spots first signs of Parkinson's disease

September 6, 2017
Researchers have developed the first tool that can diagnose Parkinson's disease when there are no physical symptoms, offering hope for more effective treatment of the condition.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.